159 related articles for article (PubMed ID: 28399113)
1. Comment on 'Renewed interest in the progesterone receptor in breast cancer'.
Simone G; Diotaiuti S; Digennaro M; Sambiasi D; De Summa S; Tommasi S; Altieri R; Mangia A; Dantona C; Paradiso A
Br J Cancer; 2017 Jul; 117(2):e1. PubMed ID: 28399113
[No Abstract] [Full Text] [Related]
2. Renewed interest in the progesterone receptor in breast cancer.
Lim E; Palmieri C; Tilley WD
Br J Cancer; 2016 Oct; 115(8):909-911. PubMed ID: 27657336
[No Abstract] [Full Text] [Related]
3. Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10.
Lehrer S; Rheinstein PH
Cancer; 2023 Jul; 129(13):2103-2104. PubMed ID: 37106560
[No Abstract] [Full Text] [Related]
4. Reply to "Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10%".
Lashen AG; Toss MS; Rakha EA
Cancer; 2023 Jul; 129(13):2105. PubMed ID: 37106558
[No Abstract] [Full Text] [Related]
5. Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer.
Altundag K
Eur J Surg Oncol; 2018 Apr; 44(4):539. PubMed ID: 29426782
[No Abstract] [Full Text] [Related]
6. Reply letter to: Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer.
Liao GS
Eur J Surg Oncol; 2018 Apr; 44(4):540. PubMed ID: 29395433
[No Abstract] [Full Text] [Related]
7. [Progesterone receptor in breast cancer: fundamental data and clinical applications].
Ojasoo T
Bull Cancer; 1996; 83 Suppl 1():1-5. PubMed ID: 8777338
[No Abstract] [Full Text] [Related]
8. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
McFall T; McKnight B; Rosati R; Kim S; Huang Y; Viola-Villegas N; Ratnam M
J Biol Chem; 2018 Jan; 293(4):1163-1177. PubMed ID: 29162724
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
Rakha EA; Ellis IO; Reis-Filho JS
Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
[No Abstract] [Full Text] [Related]
10. Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort.
Kornaga EN; Klimowicz AC; Guggisberg N; Ogilvie T; Morris DG; Webster M; Magliocco AM
Mod Pathol; 2016 Dec; 29(12):1492-1500. PubMed ID: 27562489
[TBL] [Abstract][Full Text] [Related]
11. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.
Badve S; Dabbs DJ; Schnitt SJ; Baehner FL; Decker T; Eusebi V; Fox SB; Ichihara S; Jacquemier J; Lakhani SR; Palacios J; Rakha EA; Richardson AL; Schmitt FC; Tan PH; Tse GM; Weigelt B; Ellis IO; Reis-Filho JS
Mod Pathol; 2011 Feb; 24(2):157-67. PubMed ID: 21076464
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer.
Garimella V; Long ED; O'Kane SL; Drew PJ; Cawkwell L
Acta Oncol; 2007; 46(2):204-7. PubMed ID: 17453370
[TBL] [Abstract][Full Text] [Related]
13. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.
Allred DC
Mod Pathol; 2010 May; 23 Suppl 2():S52-9. PubMed ID: 20436503
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].
Joubert C; Boissonneau S; Fina F; Figarella-Branger D; Ouafik L; Fuentes S; Dufour H; Gonçalves A; Charaffe-Jauffret E; Metellus P
Neurochirurgie; 2016 Jun; 62(3):151-6. PubMed ID: 27236733
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
Jorns JM
Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
18. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
19. Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study.
Xie M; Zhu X; Liu Z; Shrubsole M; Varma V; Mayer IA; Dai Q; Chen Q; You S
PLoS One; 2012; 7(4):e35198. PubMed ID: 22496908
[TBL] [Abstract][Full Text] [Related]
20. Comment on: Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer.
Wang B; Lu Z; Huang Y
Br J Surg; 2020 Mar; 107(4):466. PubMed ID: 32129482
[No Abstract] [Full Text] [Related]
[Next] [New Search]
